April 12, 2021
Low-dose colchicine reduces not only MACE but also MI, stroke, and the need for coronary revascularization among patients with known CAD, according to a new meta-analysis that sought to better tease out the anti-inflammatory’s protective effects.
The combined data set includes results for more than 11,000 patients, drawing from LoDoCo2, released during last year’s European Society of Cardiology Congress, as well as the 2013 LoDoCo trial, a 2013 study of colchicine in diabetic patients, the 2019 COLCOT trial, and the 2020 COPS trial. Altogether, the studies capture the evolving body of evidence that increasingly supports the inflammatory hypothesis in cardiovascular disease.
A strength of the meta-analysis is that “we aligned all the endpoints from the various papers, because each paper has its own endpoints, its own definitions,” said Jan H. Cornel, MD (Northwest Clinics, Alkmaar, and Radboud University Medical Centre, Nijmegen, the Netherlands), one of the